Citigroup Downgrades 10x Genomics to Neutral From Buy, Price Target is $18 - marketscreener.com
Citigroup Downgrades 10x Genomics to Neutral From Buy, Price Target is $18 - marketscreener.com
Citigroup Downgrades 10x Genomics to Neutral From Buy, Price Target is $18 - marketscreener.com
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.